ANTX AN2 Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why ANTX matters now
AN2 Therapeutics, Inc. (ANTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.41 with +2.56% on the session and $120.8M in market capitalization; recent performance reads 1-month +9.89% and YTD +338.60%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.0M, and EPS of $-0.29. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -22.8%.
The latest indexable market news headline is "The Healthcare M&A Wave" from Forbes.
Additional event context on this page matters because analyst consensus is Buy with a median target of $9.00; recent insider activity includes Williams Sarah Joanne filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.08
P/S
0.00
EV/EBITDA
-2.33
DCF Value
$0.59
FCF Yield
-22.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-52.3%
ROA
-39.5%
ROIC
-45.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.0M | $-0.29 |
| Q4 2025 | $0.00 | $-8.7M | $-0.29 |
| FY 2025 | $0.00 | $-35.2M | $-1.16 |
| Q3 2025 | $0.00 | $-9.4M | $-0.31 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$9.00
Target (Median)
$9.00
Target Range
$9.00 - $9.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
-0.98
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.